Search CommunityWalk:


MetaMorphix Inc

Center Park II., Suite 320,
Calverton, MD, USA

Category: Bioinformatics/Genomics/Proteomics/Pharmacogenomics

Used in the following map:

Maryland Biotech Industry Map

MetaMorphix Inc is a life science company that uses DNA, to improve the global food supply and human health. It was founded in 1994. The company's wholly owned subsidiary MMI Genomics, Inc develops innovative life science technologies to introduce environmentally friendly solutions that improve food and human and animal well being.

MetaMorphix is focused on the development of products based on two foundation technologies that include: Growth Factor technology based on Myostatin, which is encoded by the GDF-8 gene; and Genomics used to discover gene-based therapeutic and disease prevention strategies for livestock production and animal health. Its technology platforms have the potential to effect dramatic improvements in livestock production and animal and human health.

MetaMorphix is developing a pipeline of products addressing all major livestock sectors including cattle, swine, poultry and aquaculture as well as developing products that enhance the health of companion animals. Its product portfolio includes: Tru-Marbling(TM), a DNA-based genetic test that contains a panel of 128 unique DNA markers, each one highly associated with the expression for marbling score and quality grade and validated in both commercial cross-bred feeder cattle populations and in Angus cattle; Tru-Tenderness(TM), a DNA-based genetic test that contains a panel of 11 unique DNA markers, each one highly associated with expression for tender meat; MMIG Parentage and Identification; Tru-CoatColor(TM), a test that enables animal breeders to determine the genetics of coat color for the tested animal; Canine DNA Parentage Test, used to determine parents of dogs; etc.

MetaMorphix has partnerships with Sequenom Inc, Genetic Technologies Limited, Monsanto Company, Willmar Poultry Company etc.

MetaMorphix on February 4, 2011 the company announced its intention to sell all, or substantially all, of its assets as part of its reorganization under a sale in Chapter 11 pursuant to section 363 of the Bankruptcy Code. It has also announced that American MedTech Advisors has been retained to assist in the sale of the company.